Lixisenatide

Also known as: Adlyxin, Lyxumia

Weight LossFDA APPROVED

Clinical Status

FDA Approved — Type 2 diabetes as add-on therapy.

Mechanism of Action

Modified exendin-4 with C-terminal tail deletion. Short-acting GLP-1 agonist that primarily reduces postprandial glucose through potent gastric emptying delay and local gut effects.

Dosing Defaults

Dose

10-20 mcg daily

Frequency

1x daily

Administration

Subcutaneous injection

Timing

60 minutes before first meal

Food

fasted

Duration

Long-term use

Dose range: 10-20 mcg daily

Pre-meal timing maximizes postprandial glucose reduction.

Side Effects

•Nausea
•Vomiting
•Diarrhea
•Headache
•Dizziness
•Hypoglycemia (with sulfonylureas)

Contraindications & Warnings

•Not medical advice

Compare

Compare Lixisenatide with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Lixisenatide dose.

Open Calculator

Related Weight Loss Peptides

Semaglutide

FDA APPROVED

Weight Loss

GLP-1 receptor agonist. FDA-approved for type 2 diabetes and weight management.

Tirzepatide

FDA APPROVED

Weight Loss

Dual GLP-1/GIP receptor agonist. FDA-approved for T2D and weight management.

Retatrutide

PHASE 3

Weight Loss

Triple receptor agonist (GLP-1/GIP/Glucagon). Most potent weight loss peptide in trials.

AOD-9604

PHASE 2

Weight Loss

GH fragment for fat metabolism. Does NOT produce typical HGH side effects.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.